GlassScriptPhysician profile
Ann Tran
NPI 1407855430
$4,526.57
in general payments reported to CMS, 2019-2025
26 companies · $773 in 2025
The $773 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $407 · 2022: $629 · 2023: $1,085 · 2024: $1,633 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,580.51 | 2022-2025 | |
| Lilly USA, LLC | $414.66 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Janssen Biotech, INC. | $409.46 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $364.00 | 2021-2025 | Aklief, Oracea, Epsolay |
| Genzyme Corporation | $291.85 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $203.52 | 2021-2025 | Dupixent, Libtayo |
| Allergan, INC. | $203.43 | 2021 | |
| Revance Therapeutics, INC. | $153.87 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $121.96 | 2021-2023 | Absorica Ld, Winlevi |
| Mayne Pharma Commercial LLC | $114.09 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.02 | 2023-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $101.14 | 2023-2025 | |
| Journey Medical Corporation | $65.68 | 2022 | |
| Incyte Corporation | $62.52 | 2024 | Opzelura |
| Amgen INC. | $61.65 | 2023 | Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $44.95 | 2024 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $40.81 | 2023 | Nuzyra |
| Epi Health, LLC | $40.76 | 2021 | |
| Leo Pharma INC. | $25.57 | 2022 | |
| Organon LLC | $24.23 | 2025 | Nexplanon |
| Verrica Pharmaceuticals INC. | $20.60 | 2024 | Ycanth |
| Almirall LLC | $19.25 | 2024 | Seysara |
| Fidia Pharma USA INC. | $15.03 | 2024 | |
| Smith+Nephew, INC. | $14.13 | 2023 | Collagenase Santyl, Regranex |
| Merz North America, INC. | $14.12 | 2023 | |
| Nabriva Therapeutics, Plc | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.